132 related articles for article (PubMed ID: 26373952)
41. Comprehensive profiling and quantitation of oncogenic mutations in non-small cell lung carcinoma using single-molecule amplification and re-sequencing technology.
Shi J; Yuan M; Wang ZD; Xu XL; Hong L; Sun S
Tumour Biol; 2017 Feb; 39(2):1010428317691413. PubMed ID: 28218040
[TBL] [Abstract][Full Text] [Related]
42. Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.
Wetterskog D; Wilkerson PM; Rodrigues DN; Lambros MB; Fritchie K; Andersson MK; Natrajan R; Gauthier A; Di Palma S; Shousha S; Gatalica Z; Töpfer C; Vukovic V; A'Hern R; Weigelt B; Vincent-Salomon A; Stenman G; Rubin BP; Reis-Filho JS
Histopathology; 2013 Mar; 62(4):543-50. PubMed ID: 23398044
[TBL] [Abstract][Full Text] [Related]
43. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J
Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530
[TBL] [Abstract][Full Text] [Related]
44. Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma.
Lou G; Yu X; Song Z
Clin Lung Cancer; 2017 May; 18(3):e197-e201. PubMed ID: 28024928
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel
Bae GE; Yoon N; Cho EY; Kim HS; Cho SY
Anticancer Res; 2019 Jan; 39(1):369-374. PubMed ID: 30591482
[TBL] [Abstract][Full Text] [Related]
46. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.
Macarenco RS; Uphoff TS; Gilmer HF; Jenkins RB; Thibodeau SN; Lewis JE; Molina JR; Yang P; Aubry MC
Mod Pathol; 2008 Sep; 21(9):1168-75. PubMed ID: 18587327
[TBL] [Abstract][Full Text] [Related]
47. Mutation analysis of the EGFR pathway genes,
Saida K; Murase T; Ito M; Fujii K; Takino H; Masaki A; Kawakita D; Ijichi K; Tada Y; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Shinomiya H; Nibu KI; Shimozato K; Inagaki H
Oncotarget; 2018 Mar; 9(24):17043-17055. PubMed ID: 29682203
[TBL] [Abstract][Full Text] [Related]
48. [Molecular epidemiology of the lung cancer].
Guibert N; Milia JD; Mazieres J
Rev Mal Respir; 2016 Oct; 33(8):675-681. PubMed ID: 27266901
[TBL] [Abstract][Full Text] [Related]
49. [Four Cases Report on Primary Lung Adenoid Cystic Carcinoma].
He X; Chen J
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):789-792. PubMed ID: 29167011
[TBL] [Abstract][Full Text] [Related]
50. Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing.
Ricordel C; Lespagnol A; Llamas-Gutierrez F; de Tayrac M; Kerjouan M; Fievet A; Hamdi-Rozé H; Aliouat A; Desrues B; Mosser J; Léna H
Clin Lung Cancer; 2018 Mar; 19(2):163-169.e4. PubMed ID: 29129434
[TBL] [Abstract][Full Text] [Related]
51. Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review.
Chen Z; Jiang J; Fan Y; Lu H
Diagn Pathol; 2023 May; 18(1):65. PubMed ID: 37198615
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract][Full Text] [Related]
53. A new target for therapy in squamous cell carcinoma of the lung.
Ohashi K; Pao W
Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
[TBL] [Abstract][Full Text] [Related]
54. Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.
Yashima H; Shimizu K; Araki T; Aomori T; Ohtaki Y; Nagashima T; Enokida Y; Atsumi J; Nakamura T; Takeyoshi I; Yamamoto K
Mol Clin Oncol; 2014 Sep; 2(5):714-718. PubMed ID: 25054035
[TBL] [Abstract][Full Text] [Related]
55. Metanephric stromal tumor in an adult with PDGFRA mutation: a case report.
Guo S; Qian H; Zhu H; Yang Y; Yang X; Sun H
Diagn Pathol; 2023 Jul; 18(1):83. PubMed ID: 37454137
[TBL] [Abstract][Full Text] [Related]
56. Atypical manifestations of pulmonary adenoid cystic carcinoma.
Gallagher CG; Stark R; Teskey J; Kryger M
Br J Dis Chest; 1986 Oct; 80(4):396-9. PubMed ID: 3040062
[TBL] [Abstract][Full Text] [Related]
57. EGFR-Variant Adenoid Cystic Carcinoma of the Lung.
Mendes MA; Barroso A; Campainha S
J Thorac Oncol; 2018 Sep; 13(9):e178-e181. PubMed ID: 30166019
[No Abstract] [Full Text] [Related]
58. AGAP3: A novel BRAF fusion partner in pediatric pancreatic-type acinar cell carcinoma.
Paoli C; Burel-Vandenbos F; Coulomb-l'Hermine A; Cros J; Pondrom M; Kubiniek V; Pedeutour F; Dadone-Montaudié B
Genes Chromosomes Cancer; 2022 Dec; 61(12):734-739. PubMed ID: 35949061
[TBL] [Abstract][Full Text] [Related]
59. A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung.
Kumar V; Soni P; Garg M; Goyal A; Meghal T; Kamholz S; Chandra AB
Front Oncol; 2018; 8():153. PubMed ID: 29868475
[TBL] [Abstract][Full Text] [Related]
60. Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients.
Tan X; Xu T; Shen W; Ai C; Zhang W; Tang X; Luo F; Zhou Q
Thorac Cancer; 2024 Feb; 15(5):386-393. PubMed ID: 38148673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
